FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is new bispecific antigen-binding molecules containing (a) at least one antigen-binding domain having the capability of specific binding to CD40, and (b) at least one antigen-binding domain having the capability of specific binding to fibroblast-activating protein (FAP), and methods for obtaining the specified molecules, and methods for their application.
EFFECT: invention makes it possible to expand the spectrum of bispecific antibodies with a given activity.
23 cl, 25 dwg, 31 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
